What is Regeneron Pharmaceuticals Price-to-Operating-Cash-Flow?
As of today (2024-12-13), Regeneron Pharmaceuticals's share price is €732.20.
Regeneron Pharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2024 was €33.74. Hence, Regeneron Pharmaceuticals's Price-to-Operating-Cash-Flow Ratio for today is 21.70.
The historical rank and industry rank for Regeneron Pharmaceuticals's Price-to-Operating-Cash-Flow or its related term are showing as below:
MIL:1REGN'
s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.61 Med: 23.4 Max: 129.08
Current: 20.08
During the past 13 years, Regeneron Pharmaceuticals's highest Price-to-Operating-Cash-Flow Ratio was 129.08. The lowest was 7.61. And the median was 23.40.
Regeneron Pharmaceuticals's Cash Flow from Operations per share for the
three
months ended in Sep. 2024 was €10.01.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2024 was €33.74.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Regeneron Pharmaceuticals was -19.50% per year.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 21.10% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 22.00% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 25.10% per year.
During the past 13 years, Regeneron Pharmaceuticals's highest 3-Year average Operating Cash Flow per Share Growth Rate was 64.10% per year. The lowest was -80.30% per year. And the median was 21.10% per year.
Regeneron Pharmaceuticals Price-to-Operating-Cash-Flow Historical Data
The historical data trend for Regeneron Pharmaceuticals's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regeneron Pharmaceuticals Price-to-Operating-Cash-Flow Chart
|
Regeneron Pharmaceuticals Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Price-to-Operating-Cash-Flow |
|
Get a 7-Day Free Trial
|
|
|
17.71 |
21.24 |
10.01 |
16.33 |
21.74 |
|
Regeneron Pharmaceuticals Quarterly Data
|
|
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
Jun24 |
Sep24 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
17.94 |
21.74 |
23.18 |
29.51 |
28.49 |
Competitive Comparison of Regeneron Pharmaceuticals's Price-to-Operating-Cash-Flow
For the Biotechnology subindustry, Regeneron Pharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regeneron Pharmaceuticals's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Regeneron Pharmaceuticals's Price-to-Operating-Cash-Flow falls into.
Regeneron Pharmaceuticals Price-to-Operating-Cash-Flow Calculation
Regeneron Pharmaceuticals's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 732.20 | / | 33.74 |
| = | 21.70 |
Regeneron Pharmaceuticals's Share Price of today is €732.20.
Regeneron Pharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €33.74.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Regeneron Pharmaceuticals Business Description
Traded in Other Exchanges
Address
777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Regeneron Pharmaceuticals Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MIL:1REGN has been successfully added to your